目的 探讨康艾注射液联合贝伐珠单抗注射液和DP方案（多西他赛注射液+注射用顺铂）治疗非小细胞肺癌的临床疗效。方法 选取2010年1月-2013年1月昆山市第一人民医院收治的60例非小细胞肺癌患者为研究对象，将所有患者随机分为对照组（28例）和治疗组（32例）。对照组患者给予DP化疗方案，即第1天静脉滴注多西他赛注射液75 mg/m²，维持1 h；静脉滴注注射用顺铂75 mg/m²，平均分2天连续使用，维持2~6 h；然后静脉滴注贝伐珠单抗注射液15 mg/kg，1次/d。治疗组患者在对照组治疗的基础上静脉滴注康艾注射液，40 mL加入到5%葡萄糖溶液250 mL中，1次/d。3周为1个周期，两组患者治疗两个周期。观察两组的临床疗效，比较两组的生存质量、免疫功能指标、血小板指标、血管内皮生长因子（VEGF）水平、生存时间。结果 治疗后，对照组和治疗组的总有效率分别为46.43%、78.13%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者生理状况、社会家庭状况、情感情况、功能状况评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组生理状况、社会家庭状况、情感情况、功能状况评分均明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血清中CD3⁺、CD4⁺、CD4⁺/CD8⁺水平均显著升高，CD8⁺水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者免疫功能指标水平均明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者血小板（PLT）水平显著升高，血小板分布宽度（PDW）、血小板大细胞比率（P-LCR）、VEGF水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些指标均明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者生存时间明显高于对照组，两组比较差异有统计学意义（P<0.05）。结论 康艾注射液联合贝伐珠单抗注射液和DP方案治疗非小细胞肺癌具有较好的临床疗效，能改善患者凝血功能与免疫功能，降低VEGF水平，延长生存时间，具有一定的临床推广应用价值。

Objective To explore the efficacy of Kangai Injection combined with Bevacizumab Injection and DP regimen in treatment of non-small cell lung cancer. Methods Patients (60 cases) with non-small cell lung cancer in the First People's Hospital of Kunshan from January 2010 to January 2013 were randomly divided into the control group (28 cases) and the treatment group (32 cases). Patients in the control group were given DP regimen:patients in the control group were iv administered with Docetaxel Injection 75 mg/m², maintained for 1 h, and patients in the control group were iv administered with Cisplatin for injection, continuous use in 2 days on average, maintained for 2-6 h, then patients in the control group were iv administered with Bevacizumab Injection 15 mg/kg, once daily. Patients in the treatment group were iv administered with Kangai Injection on the basis of the control group, 40 mL added into 5% glucose solution 250 mL, once daily. One cycle had three weeks, and patients in two groups were treated for 2 cycles. After treatment, the clinical efficacies were evaluated, and the quality of life, the immune function indexes, the platelet indexes, the VEGF levels, and the survival time in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 46.43% and 78.13%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of physiological status, social and family status, emotional status, and functional status in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the quality of life indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, but the levels of CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the immune function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of PLT in two groups were significantly increased, but the levels of PDW, P-LCR and VEGF in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the survival times in the treatment group were significantly higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Kangai Injection combined with Bevacizumab Injection and DP regimen has clinical curative effect in treatment of non-small cell lung cancer, can coagulation function and immune function, reduce VEGF level, and prolong survival time, which has a certain clinical application value.